Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (1931)	9/30/1997 10:13:00 AM
From: Henry Niman	of 6136

John, I was focusing on the news (at least to me) which was the resistance profile. In the past I have recommended AGPH when asked, and the recommendation was based largely on projected Viracept sales. I had that the drug offered a better resisatnce profile. When I read the article in thestreet, I was a bit surprised and came over to this board. I hadn't realized that thestreet article had been mentioned the night before and posts indicated other posters hadn't noticed it either. I gave a brief synopsis and was somewhat surprised at the conspriracy mentality. Thestreet report seemed to be at odds with the general take on Viracept, so I looked for an explanation which I think is fairly clear. However, since I haven't followed AGPH that closely, I was curious about in vivio data on resistance, which no one has answered yet. AGPH's price has rebounded this morning.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next